Spinogenix, Inc., a biopharmaceutical company at the forefront of developing innovative therapies to restore synaptic function, has announced the start of enrollment for its Phase 2 clinical trial of SPG601. This study aims to assess the drug's effectiveness in treating adult men with Fragile X Syndrome (FXS), a major genetic cause of intellectual disability and autism. The U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for SPG601 and granted it Orphan Drug Designation for this condition.

Spinogenix, highlighted the importance of this development during National Fragile X Awareness Month. “The Fragile X community is exceptional but remains underrepresented in terms of treatment options. We are excited to begin this Phase 2 trial for SPG601, reflecting our commitment to improving research and treatment opportunities for those affected by FXS. Currently, there are no FDA-approved treatments for this condition. SPG601, a novel once-daily tablet, offers potential relief by enhancing BK channel activity to address specific synaptic dysfunctions associated with FXS.”

Spinogenix, added, “Families dealing with FXS face significant daily challenges. This milestone marks an important advance in our efforts to develop groundbreaking treatments that can restore synaptic function and enhance quality of life. We are eager to explore the potential of our small molecule platform, which is also being investigated for ALS and Alzheimer’s disease.”

The Phase 2 trial will use a randomized, double-blind, placebo-controlled design to evaluate a single dose of SPG601 versus a placebo in patients with Fragile X Syndrome. Enrollment is now open at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. Additional information about the trial can be found on ClinicalTrials.gov (NCT06413537).

Fragile X Syndrome results from the silencing of the Fmr1 gene, leading to disruptions in mRNA and protein expression that impact synaptic function. Many symptoms of FXS are linked to reduced activity of large-conductance, calcium-activated potassium (BK) channels. SPG601 is designed as a small molecule to activate BK channels and correct these synaptic dysfunctions. BK channel activity is also relevant to other neurodegenerative, vascular, and sensory disorders.

FXS affects approximately 1 in 4,000-5,000 men and 1 in 6,000-8,000 women worldwide. It leads to severe intellectual disability and a range of challenging symptoms, including anxiety, social aversion, hyperactivity, attention deficits, sensory hypersensitivity, aggression, and developmental seizures. The financial impact on families is substantial, with direct healthcare costs in the U.S. totaling $4.1 billion annually. Despite the significant burden, there are currently no FDA-approved drugs for FXS.

 

Source: globenewswire.com

Report Abuse